This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
Health Resources and Services Administration (HRSA), HHS.
Request for information.
HRSA, Healthcare Systems Bureau, Division of Transplantation (DoT) is in the process of information-Start Printed Page 11421gathering to assist in determining whether it should engage in rulemaking with respect to vascularized composite allografts, described more fully below. The purpose of this solicitation is to receive feedback from stakeholders and the public on the following questions: (1) Whether vascularized composite allografts should be included within the definition of organs covered by the regulations governing the operation of the Organ Procurement and Transplantation Network (OPTN) (referred to here as the “final rule”), and regulated as such, and the likely impact of such an amendment; (2) whether vascularized composite allografts should be added to the definition of human organs covered by section 301 of the National Organ Transplant Act of 1984, as amended, (NOTA) and the likely impact of such an addition; and (3) if either of these changes are pursued, the optimal way to define vascularized composite allografts for the above-described purposes.
This Request for Information is limited to information-gathering and is not a proposal to make any determinations regarding Federal oversight of vascularized composite allografts.
Written comments must be received at HRSA by May 2, 2008. Comments will be made publicly available by submitting a written request to the address below.
In addition, HRSA will hold a meeting to which the public and all stakeholders are invited for discussion and recommendations about the issues described above. The meeting will be held on Friday, April 4, 2008, from 10 a.m. to 4 p.m., at the Parklawn Building, 5600 Fishers Lane, Rockville, MD 20057.
Please send all written comments to James F. Burdick, M.D., Director, Division of Transplantation, Healthcare Systems Bureau, Health Resources and Services Administration, 5600 Fishers Lane, Room12C-06, Rockville, Maryland 20857; telephone (301) 443-7577; fax (301) 594-6095; or e-mail: firstname.lastname@example.org.
Requests to attend the meeting in person should be addressed to Elizabeth Ortiz-Rios, M.D., M.P.H., Chief Medical Officer, Division of Transplantation, Healthcare Systems Bureau, Health Resources and Services Administration, 5600 Fishers Lane, Room 12C-06, Rockville, Maryland 20857; telephone (301) 443-4423; fax (301) 594-6095; or e-mail: EOrtiz-Rios@hrsa.gov. A call-in number will be provided for individuals who would like to participate by phone. The call-in information will be posted in the `Highlights' section on the home page of http://www.organdonor.gov. If you plan to participate by phone, we request that you notify Dr. Ortiz-Rios by e-mail at EOrtiz-Rios@hrsa.gov no later than March 24, 2008, so that we can better estimate the number of phone lines that will be needed. Please include in the subject line of electronic correspondence “Vascularized Composite Allografts.”
Docket: For access to the docket to read background documents or comments received, phone (301) 443-7577 to schedule an appointment to view public comments.Start Further Info
FOR FURTHER INFORMATION CONTACT:
James F. Burdick, M.D., Director, Division of Transplantation, Healthcare Systems Bureau, Health Resources and Services Administration, at the contact information cited above.End Further Info End Preamble Start Supplemental Information
Background and General Questions
The first successful hand transplant in the United States was performed in 1999. Worldwide there have been over two dozen limb transplants, at least two transplants of portions of the face, and a small number of transplants of other such anatomical parts (e.g., abdominal wall, vascularized skeletal muscle, uterus, digits, thymus). Although the body parts involved vary significantly, two characteristics that are shared in such transplants are that they are susceptible to ischemia (damage or death from lack of blood flow) and their need for revascularization, done through a surgical reconnection of blood vessels to accomplish the transplant, as opposed to secondary ingrowth of vessels. In viable vascularized transplants, immunosuppression is necessary to prevent or treat rejection. This immunosuppression has risks, which have been justified in patients needing organs as presently defined in the final rule, because of their lifesaving potential. In the past, the risks of immunosuppression have inhibited transplantation of vascularized composite allografts because the risks associated with the prolonged use of immunosuppressive drugs were thought to exceed the expected benefits of the transplant. However, the powerful impact these transplants can have to overcome and improve the quality of life for individuals with grievous disabilities has become increasingly apparent. Coupled with this, immunosuppressive management for these transplants has improved so that risks associated with immunosuppression, such as cancer, infection, or other morbidities in recipients are lessened considerably. For these reasons, it is likely that the numbers of vascularized composite allografts transplanted will increase in the future. Given this anticipated increase, HRSA is considering the advisability of proposing that such transplants (i.e., transplants of vascularized composite allografts) be regulated under the final rule and governed by section 301 of NOTA.
HRSA is considering whether to propose that viable vascularized composite allografts, or body segments, be considered organs subject to the oversight of the OPTN under the authority of the final rule. This might be accomplished by adding vascularized composite allografts to the final rule's definition of organs through rulemaking. Currently, the final rule defines covered organs as “a human kidney, liver, heart, lung, or pancreas, or intestine (including the esophagus, stomach, small and/or large intestine, or any portion of the gastrointestinal tract). Blood vessels recovered from an organ donor during the recovery of such organ(s) are considered part of an organ with which they are procured for purposes of this part if the vessels are intended for use in organ transplantation and labeled ‘For use in organ transplantation only.’ ” Once a body part is considered an organ under the final rule, transplants involving such organs are subject to the requirements of the final rule. For example, entities performing transplants with the organs must receive designation as an organ-specific designated transplant program within an OPTN member institution. In addition, OPTN members must comply with the final rule's data submission requirements with respect to the transplants performed. In addition, OPTN members are subject to oversight by the OPTN contractor for compliance with OPTN policies regarding donor screening and allocation, and may be subject to enforcement actions for violations of such policies.
The Definition of Organs Under the Final Rule
HRSA is seeking feedback from stakeholders and from the public about the advisability of exploring rulemaking to include vascularized composite allografts within this definition of organs, as well as the potential ramifications of such a change. If, upon consideration of public comments, HRSA is persuaded that such a change may be warranted, HRSA may initiate rulemaking setting forth a more specific set of proposals. Start Printed Page 11422
For example, HRSA is interested in the public's assessment of the likely impact if OPTN policies concerning issues such as membership designation to receive organs, the retrieval of organs, allocation of organs, data collection and reporting, and OPTN policy compliance oversight were extended to vascularized composite allograft transplants. HRSA seeks feedback concerning whether regulation under the OPTN final rule would be effective in addressing special safety and allocation issues presented by vascularized composite allograft transplants as the field grows. Further, HRSA is interested in the public's assessment as to whether the clinical aspects of transplants of such vascularized composite allografts are more analogous to transplants of organs, as defined currently by the final rule, than to conventional tissue transplantation without surgical revascularization.
Presently, it is HRSA's understanding that these transplants of vascularized composite allografts are done by individual arrangements with local organ procurement organizations (OPOs) to allow retrieval of the needed structure during routine deceased donor organ retrievals. However, some of these vascularized composite allografts, e.g., testes, ovaries, or other endocrine glands, may come from living donors. HRSA is interested in perceived vulnerabilities concerning the current regulatory status of such transplants and the potential benefits of subjecting such transplants to the oversight of the OPTN and HRSA under the final rule.
The Definition of Human Organs Under Section 301 of NOTA
HRSA is also seeking feedback as to whether it should explore rulemaking to add vascularized composite allografts to the definition of human organs covered by section 301 of NOTA, as well as the potential consequences of such an action. Section 301 prohibits the purchase, sale, or other exchange for valuable consideration of human organs for transplantation. Although the statute lists covered human organs, the Secretary is authorized to add to this list through rulemaking. “Human organ,” as defined by NOTA and modified by the Secretary, means “the human (including fetal) kidney, liver, heart, lung, pancreas, bone marrow, cornea, eye, bone, skin, and intestine, including the esophagus, stomach, small and/or large intestine, or any portion of the gastrointestinal tract.” Adding to the definition of human organs covered by section 301 would make transfers of organs meeting the statute's requirements subject to its criminal sanctions. If, after receiving public comments, HRSA is persuaded that a change to this definition may be appropriate, HRSA may initiate rulemaking setting forth a more specific set of proposals.
Defining Vascularized Composite Allografts
To assist the Secretary in the event that he proposes, through rulemaking, to add vascularized composite allografts to the definition of organs covered by the final rule and/or to the definition of human organs governed by section 301 of NOTA, HRSA seeks feedback from stakeholders and from the public as to how such allografts should be defined. HRSA has identified two potential approaches.
Under the first approach, a regulatory definition could be broad, describing the features of the allografts without listing particular body parts. Under such an approach, the definition might extend to transplants of body parts that are not known to have been performed clinically to date, or even to body parts whose transplantation has not yet been envisioned. HRSA is interested in what elements would need to be included in such a definition in order to be broad enough to cover the universe of intended body parts, but narrow enough to put the public on notice as to which parts meet the regulatory definitions of organs. Shared characteristics that might be included in a regulatory definition could include some or all of the following: (1) A vascularized allograft containing multiple tissue types; (2) recovered from a human donor as an anatomical/structural unit; (3) transplanted into a human recipient as an anatomical/structural unit; (4) minimally manipulated, as defined by FDA in Title 21 CFR 1271.3(f); (5) for homologous use as defined by FDA in Title 21 CFR 1271.3(c); (6) not combined with another article such as a device; (7) used fresh and not cryopreserved; (8) susceptible to ischemia and, therefore, only stored temporarily (e.g., cold storage in preservation medium and intended for implantation into a recipient within hours of the recovery); and (9) susceptible to allograft rejection which requires immunosuppression that may increase infectious disease risk to the recipient. HRSA seeks feedback from the public as to whether some or all of these characteristics describe vascularized composite allografts, which would be included in the definition of organ. HRSA invites feedback on such an approach as well as the particular characteristics listed here and invites suggestions concerning the advisability of including any additional characteristics.
Under a second alternative, HRSA could propose a definition that lists specific body parts to be added to the definition of organs (e.g., face, hand, etc.). HRSA seeks feedback as to the feasibility of creating such a definition, which body parts should be included in such a definition, and whether such a definition would necessarily exclude certain body parts for which transplantation might be possible, but has not been performed to date (either in the United States or internationally).
Following this comment period and meeting, if HRSA decides to proceed with rulemaking to include vascularized composite allografts in the definition of organ, this decision will be written and published as a Notice of Proposed Rulemaking.Start Signature
Dated: February 20, 2008.
Elizabeth M. Duke,
[FR Doc. E8-3994 Filed 2-29-08; 8:45 am]
BILLING CODE 4165-15-P